Polyarteritis nodosa (PAN) is a necrotizing vasculitis, predominantly involving medium-sized arteries, that causes systemic disease, and, less commonly, cutaneous-limited disease. The population prevalence for PAN ranges from 2 to 33 per million.1-3 Estimates vary due to the increased recognition and classification of other forms of vasculitides over time and variation in the regional prevalence of…
ATLANTA—The ACR released a summary of its updated guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in September. Many patients take glucocorticoids for a variety of inflammatory conditions, and anyone who is taking glucocorticoid medications and has other risk factors for osteoporosis increases their risk of developing glucocorticoid-induced osteoporosis. New osteoporosis medications and new…
Belimumab is now FDA approved to treat children aged 5 years and older with active lupus nephritis, providing treatment options for pediatric patients at risk of developing renal damage.
Similar patterns of inflammation occur in the joints of patients with inflammatory arthritis, but in each individual, arthritis affects only a subset of possible anatomic areas. Chang et al. set out to identify patient-specific anatomic patterns of joint flare to distinguish local from systemic drivers of chronic disease.
In 2021, the ACR—in concert with the Vasculitis Foundation (VF)—released four new vasculitis guidelines, one each on: 1) anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 2) giant cell arteritis (GCA) and Takayasu arteritis, 3) polyarteritis nodosa and 4) Kawasaki disease. The guideline development process is complex. For the vasculitis guidelines, this process kicked off in June…
Rheumatologists should take an active role in patients’ reproductive health, including before, during and after pregnancy. Two experts offer insights into how rheumatologists can better care for their patients during these critical times.
The 2017 recommendations are updated to reflect changes in medical literature, as well as to include newly approved drugs.
Thomas Dörner, MD, reviewed the current state of systemic lupus erythematosus (SLE) management, providing updates on novel therapies and insights into the pathogenesis of SLE.
Although progress has been made in recent years, rheumatologists still have a lot of questions regarding best management practices for antiphospholipid syndrome (APS). During a session of EULAR 2022, Ricard Cervera, MD, PhD, described a holistic approach.
From the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening…